Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Amit JoshiVanita NoronhaVijay Maruti PatilAnuradha ChouguleAtanu BhattacharjeeRajiv KumarSupriya GoudSucheta MoreAnant RamaswamyAshay KarpeNikhil PandeArun ChandrasekharanAlok GoelVikas TalrejaAbhishek MahajanAmit JanuNilendu PurandareKumar PrabhashPublished in: Chemotherapy research and practice (2017)
Exon 19 deletion has no impact on PFS and OS in EGFR-mutated patients treated with second-line pemetrexed-carboplatin.